- Home
- SRTS vs ESLA Comparison
SRTS vs ESLA Comparison
Compare SRTS & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRTS | ESLA |
|---|---|---|
| Founded | 2010 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.3M | 45.6M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | SRTS | ESLA |
|---|---|---|
| Price | $2.71 | $1.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $7.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 60.1K | 29.9K |
| Earning Date | 05-07-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,482,000.00 | N/A |
| Revenue This Year | $2.00 | N/A |
| Revenue Next Year | $34.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.66 | $0.78 |
| 52 Week High | $5.92 | $3.15 |
Technical Indicators
Market Signals| Indicator | SRTS | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 30.66 | 38.37 |
| Support Level | N/A | $1.00 |
| Resistance Level | $3.28 | $1.31 |
| Average True Range (ATR) | 0.17 | 0.11 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 8.30 | 15.95 |
Price Performance
Historical ComparisonAbout SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.